Abstract
Recent common coronavirus (CCV) infections are associated with reduced COVID-19 severity upon SARS-CoV-2 infection, however the immunological mechanisms involved are unknown. We completed serological assays using samples collected from health care workers to identify antibody types associated with SARS-CoV-2 protection and COVID-19 severity. Rare SARS-CoV-2 cross-reactive antibodies elicited by past CCV infections were not associated with protection; however, the duration of symptoms following SARS-CoV-2 infections was significantly reduced in individuals with higher common betacoronavirus (βCoV) antibody titers. Since antibody titers decline over time after CCV infections, individuals in our cohort with higher βCoV antibody titers were more likely recently infected with common βCoVs compared to individuals with lower antibody titers. Therefore, our data suggest that recent βCoV infections potentially limit the severity of SARS-CoV-2 infections through mechanisms that do not involve cross-reactive antibodies. Our data are consistent with the emerging hypothesis that cellular immune responses elicited by recent common βCoV infections transiently reduce disease severity following SARS-CoV-2 infections.
Competing Interest Statement
I.F. is a consultant for Gilead Sciences and ViiV Healthcare, and has received research support from Sanofi Pasteur for work unrelated to this report. E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Elstar, Janssen, Related Sciences, Synthekine and Surface Oncology. E.J.W. is a founder of Surface Oncology and Arsenal Biosciences. E.J.W. is an inventor on a patent (U.S. patent number 10,370,446) submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer. D.J.R. is on scientific advisory boards for Alnylam, Metrea, Novartis, Pfizer and Verve, is a consultant for and receives research support from Regeneron for work unrelated to this report, and is a founder of Vascular Strategies and Staten Biotechnologies. S.E.H. has received consultancy fee from Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report.
Clinical Trial
No clinical trial ID for this prospective study
Funding Statement
This work was supported by institutional funds from the University of Pennsylvania and NIH U19AI082630 (EJW and SEH) and UM1AI069534 (IF). A.B. and J.W. were supported by the NIH award number UL1TR001878. EMA was supported by the NIH Training in Virology T32 Program (T32AI007324) and CPA was supported by the NIH Emerging Infectious Diseases T32 Program (T32AI055400). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. We thank J. Lurie, J. Embiid, J. Harris, and D. Blitzer and J. and M. Greenberg for philanthropic support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of the University of Pennsylvania under IRB #842847.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Statement: I.F. is a consultant for Gilead Sciences and ViiV Healthcare, and has received research support from Sanofi Pasteur for work unrelated to this report. E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Elstar, Janssen, Related Sciences, Synthekine and Surface Oncology. E.J.W. is a founder of Surface Oncology and Arsenal Biosciences. E.J.W. is an inventor on a patent (U.S. patent number 10,370,446) submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer. D.J.R. is on scientific advisory boards for Alnylam, Metrea, Novartis, Pfizer and Verve, is a consultant for and receives research support from Regeneron for work unrelated to this report, and is a founder of Vascular Strategies and Staten Biotechnologies. S.E.H. has received consultancy fee from Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report.
Data Availability
All data are included in the manuscript.
